New Aspects of Gene-Silencing for the Treatment of Cardiovascular Diseases

Pharmaceuticals

Olivia Koenig¹  Tobias Walker¹  Nadja Perle¹  Almuth Zech¹  Bernd Neumann¹  Christian Schlensak¹  Hans-Peter Wendel² 

[1] id="af1-pharmaceuticals-06-00881">Clinical Research Laboratory, Dept. of Thoracic, Cardiac and Vascular Surgery, University Hospital Tuebingen, Calwerstr. 7/1, 72076 Tuebingen, Germa

关键词: RNAi;    siRNA;    ASO;    transfection tools;    delivery systems;    atherosclerosis;    CVD (cardiovascular disease);    restenosis;    drug eluting stents;   

DOI  :  10.3390/ph6070881

来源: mdpi

【 摘 要 】

Coronary heart disease (CHD), mainly caused by atherosclerosis, represents the single leading cause of death in industrialized countries. Besides the classical interventional therapies new applications for treatment of vascular wall pathologies are appearing on the horizon. RNA interference (RNAi) represents a novel therapeutic strategy due to sequence-specific gene-silencing through the use of small interfering RNA (siRNA). The modulation of gene expression by short RNAs provides a powerful tool to theoretically silence any disease-related or disease-promoting gene of interest. In this review we outline the RNAi mechanisms, the currently used delivery systems and their possible applications to the cardiovascular system. Especially, the optimization of the targeting and transfection procedures could enhance the efficiency of siRNA delivery drastically and might open the way to clinical applicability. The new findings of the last years may show the techniques to new innovative therapies and could probably play an important role in treating CHD in the future.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland.